Gedatolisib, Faslodex, and Ibrance combination significantly improved progression-free survival in advanced breast cancer patients, reducing disease progression risk by 76%. The triplet regimen ...
New data on treatment for newly diagnosed pulmonary arterial hypertension (PAH) show initial treatment for the progressive disease that includes macitentan has potential to reduce risk of disease ...
Peter Voorhees, MD, of Atrium Health Levine Cancer Institute, discusses data from the MonumenTAL-3 study (NCT05455320), a ...
Mezigdomide plus carfilzomib/dexamethasone halved progression/death risk (HR 0.48), extending median PFS to 18.0 months versus 8.3 months with Kd. Enrollment captured ...
Multiple immunotherapy combinations are already duking it out in newly diagnosed kidney cancer. Now, Exelixis is throwing another hat in the ring, hoping a triplet based on two Bristol Myers Squibb ...
PARIS -- Adding the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) to dual immune checkpoint inhibition improved progression-free survival (PFS) in patients with advanced renal cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results